These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18979516)

  • 1. Tumor cell recognition by the NK cell activating receptor NKG2D.
    Bryceson YT; Ljunggren HG
    Eur J Immunol; 2008 Nov; 38(11):2957-61. PubMed ID: 18979516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK cells and cancer immunosurveillance.
    Waldhauer I; Steinle A
    Oncogene; 2008 Oct; 27(45):5932-43. PubMed ID: 18836474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NKG2D ligands in tumor immunity.
    Nausch N; Cerwenka A
    Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral inhibitors of NKG2D ligands: friends or foes of immune surveillance?
    Jonjić S; Polić B; Krmpotić A
    Eur J Immunol; 2008 Nov; 38(11):2952-6. PubMed ID: 18979514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NKG2D and cytotoxic effector function in tumor immune surveillance.
    Hayakawa Y; Smyth MJ
    Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the NKG2D receptor for tumor immunity.
    Coudert JD; Held W
    Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKG2D ligands: key targets of the immune response.
    González S; López-Soto A; Suarez-Alvarez B; López-Vázquez A; López-Larrea C
    Trends Immunol; 2008 Aug; 29(8):397-403. PubMed ID: 18602338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.
    Maccalli C; Nonaka D; Piris A; Pende D; Rivoltini L; Castelli C; Parmiani G
    Clin Cancer Res; 2007 Dec; 13(24):7459-68. PubMed ID: 18094430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate immune recognition and suppression of tumors.
    Hayakawa Y; Smyth MJ
    Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway.
    Le Maux Chansac B; Missé D; Richon C; Vergnon I; Kubin M; Soria JC; Moretta A; Chouaib S; Mami-Chouaib F
    Int Immunol; 2008 Jul; 20(7):801-10. PubMed ID: 18441340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunosurveillance: NKG2D breaks cover.
    Ljunggren HG
    Immunity; 2008 Apr; 28(4):492-4. PubMed ID: 18400193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKG2D signaling in cancer immunosurveillance.
    López-Soto A; Huergo-Zapico L; Acebes-Huerta A; Villa-Alvarez M; Gonzalez S
    Int J Cancer; 2015 Apr; 136(8):1741-50. PubMed ID: 24615398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
    Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
    Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NKG2D receptor: sensing stressed cells.
    López-Larrea C; Suárez-Alvarez B; López-Soto A; López-Vázquez A; Gonzalez S
    Trends Mol Med; 2008 Apr; 14(4):179-89. PubMed ID: 18353724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function.
    Hedlund M; Stenqvist AC; Nagaeva O; Kjellberg L; Wulff M; Baranov V; Mincheva-Nilsson L
    J Immunol; 2009 Jul; 183(1):340-51. PubMed ID: 19542445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
    Kopp HG; Placke T; Salih HR
    Cancer Res; 2009 Oct; 69(19):7775-83. PubMed ID: 19738039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.
    Mincheva-Nilsson L; Baranov V
    Semin Cancer Biol; 2014 Oct; 28():24-30. PubMed ID: 24602822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
    Wittenbrink M; Spreu J; Steinle A
    Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK cells: new issues and challenges. Preface.
    Colonna M
    Eur J Immunol; 2008 Nov; 38(11):2927-9. PubMed ID: 18979520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.